Camptosar en es it fr

Camptosar Brand names, Camptosar Analogs

Camptosar Brand Names Mixture

  • No information avaliable

Camptosar Chemical_Formula


Camptosar RX_link

Camptosar fda sheet

Camptosar FDA

Camptosar msds (material safety sheet)

Camptosar MSDS

Camptosar Synthesis Reference

T. Miyasaka et al., U.S. pat. 4,604,463 (1985, 1986 both to Yakult Honsha)

Camptosar Molecular Weight

586.678 g/mol

Camptosar Melting Point

222-223 oC

Camptosar H2O Solubility


Camptosar State


Camptosar LogP


Camptosar Dosage Forms

Solution for IM injection

Camptosar Indication

For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin).

Camptosar Pharmacology

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of Irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either Irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks. The precise contribution of SN-38 to the activity of Irinotecan in humans is not known. Irinotecan is cell cycle phase-specific (S-phase).

Camptosar Absorption


Camptosar side effects and Toxicity

Gastrointestinal complications, such as nausea, vomiting, abdominal cramping, diarrhea, and infection.

Camptosar Patient Information

Camptosar Organisms Affected

Humans and other mammals